To further confirm the direct role of intra‐tumor effector CD8+ T cell in improved combinatorial efficacy, animals were treated with four doses of DR5 agonist + ROCK1 inhibitor (and avelumab). This evidence concerns the gene TNFRSF10B and neoplasm.